Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

MiMedx Group, Inc (MDXG) vs Silence Therapeutics PLC Sponsored ADR (SLN)

MiMedx Group, Inc and Silence Therapeutics PLC Sponsored ADR are both Biotechnology companies. MiMedx Group, Inc and Silence Therapeutics PLC Sponsored ADR are of similar size ($697.3M and $686.5M). Silence Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; MiMedx Group, Inc trades at 117×. MiMedx Group, Inc grew revenue faster over the last twelve months: −2.36% against −97.0%. MiMedx Group, Inc has the higher net margin (1.76% vs 0.00%) and the higher return on invested capital (5.62% vs 0.00%). Across the 18 metrics below, MiMedx Group, Inc leads on 15 and Silence Therapeutics PLC Sponsored ADR on 3.

Valuation

Metric MDXG SLN Biotechnology median
P/E 116.75 n/m 7.88
P/S 1.94 629.45 11.47
P/B 3.20 13.73 2.52
Price to free cash flow 15.53 n/m 21.16
EV/EBITDA 28.01 n/m 0.74
EV/Sales 1.61 543.65 10.73
Earnings yield 0.86% (11.45%) (28.84%)
Free cash flow yield 6.44% (8.01%) (23.03%)

Profitability

Metric MDXG SLN Biotechnology median
Gross margin 78.85% 79.50% 65.16%
Operating margin 2.46% 0.00% 0.00%
Net margin 1.76% 0.00% 0.00%
Free cash flow margin 12.51% 0.00% 0.00%
Return on equity 2.88% (90.41%) (57.72%)
Return on assets 2.18% (44.14%) (49.22%)
Return on invested capital 5.62% 0.00% 0.00%

Growth

Metric MDXG SLN Biotechnology median
Revenue growth (TTM) (2.36%) (96.97%) 5.64%
EPS growth (last fiscal year) 14.29% (90.91%) —
Revenue growth, 5-year CAGR 11.02% (39.74%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MDXG SLN Biotechnology median
Debt to equity 0.08 0.00 0.00
Current ratio 5.33 7.42 4.73
Net debt to EBITDA (1.88) 0.94 0.96

Dividend

Metric MDXG SLN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MDXG SLN Biotechnology median
Market cap 686.53m 697.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack